Novo Nordisk's Etavopivat Phase 3 Trial Achieves Key Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NVO?
Source: NASDAQ.COM
- Trial Results: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that Etavopivat met both co-primary endpoints in 385 patients with sickle cell disease, significantly outperforming placebo.
- Efficacy Highlights: Patients treated with Etavopivat experienced a 27% reduction in the annualized rate of vaso-occlusive crises (VOCs), with 48.7% achieving a hemoglobin increase of over 1g/dL after 24 weeks, compared to just 7.2% in the placebo group.
- Safety Profile: The trial indicated that Etavopivat was well tolerated, with a safety profile consistent with previous studies, suggesting a favorable risk-benefit ratio for future use.
- Future Prospects: Novo Nordisk plans to submit for regulatory approval of Etavopivat in the second half of 2026, with the FDA granting it Fast Track, Rare Pediatric Disease, and Orphan Drug designations, highlighting its significant market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 40.930
Low
42.00
Averages
54.67
High
70.00
Current: 40.930
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Etavopivat Trial Achieves Success
- Trial Success: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that etavopivat significantly reduced vaso-occlusive crises and improved hemoglobin response in 385 patients aged 12 and older over 52 weeks, achieving both co-primary endpoints and confirming the drug's efficacy.
- Safety Profile: The therapy exhibited a safety profile consistent with prior studies, indicating good tolerability, which enhances its potential for clinical application and may offer patients a safer treatment option for sickle cell disease.
- Regulatory Submission Plans: Novo Nordisk intends to submit a regulatory application for etavopivat in H2 2026, marking a critical step toward market entry, and if approved, it could provide new treatment options for sickle cell disease patients.
- Future Results Presentation: The company plans to present detailed trial results at an upcoming medical event, which could further drive interest and research into the drug, potentially attracting more investors and healthcare professionals to its innovative treatment approach.
See More
Novo Nordisk's Etavopivat Phase 3 Trial Achieves Key Success
- Trial Results: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that Etavopivat met both co-primary endpoints in 385 patients with sickle cell disease, significantly outperforming placebo.
- Efficacy Highlights: Patients treated with Etavopivat experienced a 27% reduction in the annualized rate of vaso-occlusive crises (VOCs), with 48.7% achieving a hemoglobin increase of over 1g/dL after 24 weeks, compared to just 7.2% in the placebo group.
- Safety Profile: The trial indicated that Etavopivat was well tolerated, with a safety profile consistent with previous studies, suggesting a favorable risk-benefit ratio for future use.
- Future Prospects: Novo Nordisk plans to submit for regulatory approval of Etavopivat in the second half of 2026, with the FDA granting it Fast Track, Rare Pediatric Disease, and Orphan Drug designations, highlighting its significant market potential.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Eli Lilly's Tirzepatide Shows Superior Weight Loss Effects Compared to Semaglutide
- Efficacy Comparison: A new study indicates that Eli Lilly's obesity therapy tirzepatide leads to greater weight loss compared to Novo Nordisk's semaglutide, showing LBM losses of 1.1%, 1.5%, 1.3%, and 2.0% greater at 3, 6, 9, and 12 months respectively, highlighting tirzepatide's significant advantage in weight reduction.
- Patient Data Analysis: The study analyzed data from 1,800 patients on tirzepatide and 6,200 on semaglutide, revealing that tirzepatide not only resulted in greater total body weight loss but also reinforced its competitive position in the market for GLP-1 drugs.
- Market Impact: Findings suggest that patients should not simply focus on the amount of weight loss when choosing weight loss medications, but also consider the impact on body composition, which could influence future prescription trends, especially following the launch of Eli Lilly's Zepbound and Mounjaro.
- Industry Competition: As Eli Lilly's tirzepatide demonstrates increasing advantages in the weight loss sector, Novo Nordisk's semaglutide faces intensified market competition, potentially prompting adjustments in product development and market strategies.
See More
Novo Nordisk and Eli Lilly Prescription Comparison
- Prescription Comparison: Novo Nordisk's oral obesity drug Wegovy received 3,071 prescriptions in its first four days post-launch in the U.S., while Eli Lilly's Foundayo garnered 1,390 prescriptions in its debut week, indicating a strong market presence for Novo Nordisk despite Lilly's promising start.
- Cardiovascular Risk Reduction: Eli Lilly's ACHIEVE-4 trial revealed that patients taking Foundayo had a 16% lower risk of major adverse cardiovascular events compared to those on insulin glargine, providing robust support for the drug's safety profile and potentially boosting market confidence.
- Usage Restrictions: Wegovy must be taken on an empty stomach with a 30-minute fasting period, whereas Foundayo can be consumed without food restrictions, which may enhance its appeal among patients and impact market share dynamics.
- Market Sentiment Shift: Retail sentiment on Stocktwits regarding Eli Lilly shifted from 'bearish' to 'neutral', with message volumes increasing from 'low' to 'normal', reflecting growing confidence in Lilly's obesity treatments and potentially driving its stock price upward.
See More
Novo Nordisk's Etavopivat Trial Achieves Success
- Trial Success: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that etavopivat significantly reduced vaso-occlusive crises and improved hemoglobin response in 385 patients aged 12 and older over 52 weeks, achieving both co-primary endpoints and confirming the drug's efficacy.
- Safety Profile: The therapy exhibited a safety profile consistent with prior studies, indicating good tolerability, which enhances its potential for clinical application and may offer patients a safer treatment option for sickle cell disease.
- Regulatory Submission Plans: Novo Nordisk intends to submit a regulatory application for etavopivat in H2 2026, marking a critical step toward market entry, and if approved, it could provide new treatment options for sickle cell disease patients.
- Future Results Presentation: The company plans to present detailed trial results at an upcoming medical event, which could further drive interest and research into the drug, potentially attracting more investors and healthcare professionals to its innovative treatment approach.
See More
Novo Nordisk's Etavopivat Phase 3 Trial Achieves Key Success
- Trial Results: Novo Nordisk's HIBISCUS Phase 3 trial demonstrated that Etavopivat met both co-primary endpoints in 385 patients with sickle cell disease, significantly outperforming placebo.
- Efficacy Highlights: Patients treated with Etavopivat experienced a 27% reduction in the annualized rate of vaso-occlusive crises (VOCs), with 48.7% achieving a hemoglobin increase of over 1g/dL after 24 weeks, compared to just 7.2% in the placebo group.
- Safety Profile: The trial indicated that Etavopivat was well tolerated, with a safety profile consistent with previous studies, suggesting a favorable risk-benefit ratio for future use.
- Future Prospects: Novo Nordisk plans to submit for regulatory approval of Etavopivat in the second half of 2026, with the FDA granting it Fast Track, Rare Pediatric Disease, and Orphan Drug designations, highlighting its significant market potential.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Eli Lilly's Tirzepatide Shows Superior Weight Loss Effects Compared to Semaglutide
- Efficacy Comparison: A new study indicates that Eli Lilly's obesity therapy tirzepatide leads to greater weight loss compared to Novo Nordisk's semaglutide, showing LBM losses of 1.1%, 1.5%, 1.3%, and 2.0% greater at 3, 6, 9, and 12 months respectively, highlighting tirzepatide's significant advantage in weight reduction.
- Patient Data Analysis: The study analyzed data from 1,800 patients on tirzepatide and 6,200 on semaglutide, revealing that tirzepatide not only resulted in greater total body weight loss but also reinforced its competitive position in the market for GLP-1 drugs.
- Market Impact: Findings suggest that patients should not simply focus on the amount of weight loss when choosing weight loss medications, but also consider the impact on body composition, which could influence future prescription trends, especially following the launch of Eli Lilly's Zepbound and Mounjaro.
- Industry Competition: As Eli Lilly's tirzepatide demonstrates increasing advantages in the weight loss sector, Novo Nordisk's semaglutide faces intensified market competition, potentially prompting adjustments in product development and market strategies.
See More
Novo Nordisk and Eli Lilly Prescription Comparison
- Prescription Comparison: Novo Nordisk's oral obesity drug Wegovy received 3,071 prescriptions in its first four days post-launch in the U.S., while Eli Lilly's Foundayo garnered 1,390 prescriptions in its debut week, indicating a strong market presence for Novo Nordisk despite Lilly's promising start.
- Cardiovascular Risk Reduction: Eli Lilly's ACHIEVE-4 trial revealed that patients taking Foundayo had a 16% lower risk of major adverse cardiovascular events compared to those on insulin glargine, providing robust support for the drug's safety profile and potentially boosting market confidence.
- Usage Restrictions: Wegovy must be taken on an empty stomach with a 30-minute fasting period, whereas Foundayo can be consumed without food restrictions, which may enhance its appeal among patients and impact market share dynamics.
- Market Sentiment Shift: Retail sentiment on Stocktwits regarding Eli Lilly shifted from 'bearish' to 'neutral', with message volumes increasing from 'low' to 'normal', reflecting growing confidence in Lilly's obesity treatments and potentially driving its stock price upward.
See More
